Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly

Phase 4

Completed

• Conditions: Squamous Cell Carcinoma; Adenocarcinoma; Carcinoma, Large Cell; Non-Small Cell Lung Cancer; Carcinoma; Lung Neoplasm
• Interventions: Drug: nab-paclitaxel; Drug: Carboplatin

• Registration Number: NCT02151149
• Lead Sponsor: Celgene

Brief Summary

Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC

Detailed Description

This is a Phase IV, randomized, open-label, multicenter study of continuous weekly versus weekly times three with one-week break nab-paclitaxel in combination with carboplatin as first-line treatment in elderly subjects (≥ 70 years old) with advanced non small cell lung cancer who have not received prior chemotherapy for their advanced disease and are not candidates for curative surgery or radiation therapy. The primary study endpoint is the percentage of subjects with either peripheral neuropathy or myelosuppression adverse events. Patients will continue treatment until they develop progressive disease, unacceptable side-effects or wish to withdraw from the study, according to local standard of care. Patients will have radiographic evaluations every 6 weeks while on treatment.

Study Timeline

• Study First Submitted: 2014-05-28
• Study First Submitted QC: 2014-05-28
• Study First Posted: 2014-05-30
• Study Start: 2014-06-09
• Primary Completion: 2017-07-14
• Study Completion: 2017-07-14
• Results First Submitted: 2018-07-13
• Status Verified: 2018-08
• Results First Submitted QC: 2018-08-20
• Last Update Submitted: 2018-08-20
• Results First Posted: 2018-09-24
• Last Update Posted: 2018-09-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 143

Inclusion Criteria

• Inclusion Criteria: -

  1. Age ≥ 70 years at the time of signing the Informed Consent Form.
  2. Understand and voluntarily provide written informed consent prior to the conduct of any study related assessments/procedures.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Histologically or cytologically confirmed locally advanced or metastatic non small cell lung cancer who are not candidates for curative surgery or radiation therapy.
  5. No other current active malignancy requiring anticancer therapy.
  6. Radiographically documented measurable disease per RECIST v 1.1
  7. No prior chemotherapy for the treatment of metastatic disease. Adjuvant chemotherapy is permitted providing that cytotoxic chemotherapy was completed 12 months prior to signing the informed consent form (ICF) and without disease recurrence. Participans with previously known epidermal growth factor receptor mutation or anaplastic lymphoma kinase gene translocation must have failed or had intolerance to one treatment with epidermal growth factor receptor tyrosine kinase inhibitor or anaplastic lymphoma kinase inhibitor therapy, respectively.
  8. Absolute neutrophil count ≥ 1500 cells/cubic millimetre.
  9. Platelets ≥ 100,000 cells/cubic millimetre.
  10. Hemoglobin ≥ 9 grams/decilitre.
  11. Aspartate transaminase/serum glutamic oxaloacetic transaminase/ alanine transaminase/serum glutamic pyruvic transaminase ≤ 2.5 × upper limit of normal range or ≤ 5.0 × upper limit of normal range if liver metastases.
  12. Total bilirubin ≤ 1.5 millilitre/decilitre (unless there is a known history of Gilberts Syndrome).
  13. Creatinine clearance > 40 millilitre/minute calculated using Cockcroft-Gault equation (if renal impairment is suspected 24 hour urine collection for measurement is required).
  14. Eastern Cooperative Oncology Group performance status 0 or 1.
  15. Females who (1) have undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have been naturally postmenopausal for at least 24 consecutive months (ie, has not had menses at any time during the preceding 24 consecutive months).
  16. Male subjects must: Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following study drug discontinuation, even if he has undergone a successful vasectomy.

Exclusion Criteria

• 1. Evidence of active brain metastases, including leptomeningeal involvement (prior evidence of brain metastasis are permitted only if treated and stable and off therapy for ≥ 4 weeks prior to signing Informed consent form. Magnetic Resonance Imaging of the brain (or Computed Tomography scan w/contrast) is preferred for diagnosis.

  2. History of leptomeningeal disease. 3. Only evidence of disease is non measurable. 4. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology Criteria for Adverse Events v4.0).

  3. Participant has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting investigational product, and/or from whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.

  4. Venous thromboembolism within 1 month prior to signing informed consent form.

  5. Current congestive heart failure (New York Heart Association Class II-IV). 8. History of the following within 6 months prior to first administration of a study drug: a myocardial infarction, severe/unstable angina pectoris,coronary/peripheral artery bypass graft, New York Heart Association Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant Electrocardiogram abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder.

  6. Participant has a known infection with hepatitis B or C, or history of human immunodeficiency virus infection, or participant is receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.

  7. Participant has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.

  11.History of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or pulmonary hypersensitivity pneumonitis.

  12. Treatment with any investigational product within 28 days prior to signing the informed consent form.

  13. History of allergy or hypersensitivity to nab-paclitaxel or carboplatin. 14. Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices. 15. Any other clinically significant medical condition, psychiatric illness, and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol or which, in the views of investigator, preclude combination chemotherapy.

  14. Participant has any other malignancy within 5 years prior to randomization. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer Tumor, Lymph Node, Metastatic (TNM stage of T1a or T1b). All treatment of which should have been completed 6 months prior to signing Informed consent form.

  15. Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.

  16. Any medical condition that confounds the ability to interpret data from the study.

  17. Females who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)	nab-paclitaxel	nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg\*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)	nab-paclitaxel	nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg\*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)	Carboplatin	nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg\*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)	Carboplatin	nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg\*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values	From the date of the first dose of investigational product (IP) until 28 days after the last dose of IP; up to data cut-off date of 20 November 2016; The median treatment duration for Arms A and B were 3.04 months and 5.17 months respectively.	Peripheral neuropathy (sensory or motor) assessment was done at screening, on Days 1, 8, 15 of every treatment cycle, at the End-of-Treatment visit and at the 28-day Follow-up Visit. Changes in neuropathy grade from baseline was reported as an AE as assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Myelosuppression in participants receiving chemotherapy may have manifested as neutropenia, thrombocytopenia, or anemia. Grade 3 neutropenia including an absolute neutropenia count (ANC) of 500 to 1,000 cells/mm\^3; anemia hemoglobain levels (Hgb) \<8.0 - 6.5 g/dL; \<4.9 - 4.0 mmol/L; \<80 - 65 g/L; transfusion indicated; and thrombocytopenia with platelet levels \<100,000 cells/mm\^3.

Secondary Outcome Measures

Name	Time	Method
Kaplan Meier Estimate of Overall Survival (OS)	From first dose of IP to the date of death due to any cause; up to a later clinical cut-off date of 14 July 2017; for Arms A and B participants were followed for OS for 31 months and 33 months respectively	Overall survival was defined as the time in months between day 1 of treatment and death from any cause). Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact.
Number of Participants With Treatment Emergent Adverse Events During the Treatment Period	From the date of the first dose of IP until 28 days after the last dose of IP; up to a later data cut-off date of 14 July 2017; maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively.	Treatment-emergent adverse events (TEAEs) were defined as any AE or serious adverse event (SAE) that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP. Any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and based on the scale: Grade 1 = Mild - transient or mild discomfort; Grade 2 = Moderate - mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required; Grade 3 = Severe - marked limitation in activity, assistance usually required; medical intervention required, hospitalization is possible; Grade 4 = Life threatening - extreme limitation in activity, assistance required; medical intervention, hospitalization or hospice care probable; Grade 5 = death.
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn	From the date of the first dose of IP until 28 days after the last dose of IP; up to a later data cut-off date of 14 July 2017 the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively	The percentage of participants with at least 1 TEAE with action taken as studydrug withdrawn during the treatment period of the trial was assessed throughout the conduct of the study. Study drug withdrawn (treatment permanently discontinued) was attributed to the part in which the onset of the adverse event took place.
Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study	From day 1 of study treatment to the end date of study treatment; up to data cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively	Dose intensity was the cumulative dose divided by the dosing period in weeks.
Percentage of Participants With Dose Reductions During the Entire Study	From the first dose of study treatment to discontinuation date of study treatment; up to date cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively	A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.
Dose Intensity Per Week of Carboplatin During the Entire Study	From day 1 of study treatment to the end date of study treatment; up to data cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively	Dose intensity for carboplatin was the cumulative dose divided by the dosing period in weeks."
Percentage of Participants With a Dose Delay During the Entire Study	From the first dose of study treatment to discontinuation date of study treatment; up to date cut off date of 16 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively	A dose delay occurred when the dose assigned at a visit was held compared to the previous visit. Dose delays were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.
Kaplan Meier Estimate of Progression-Free Survival (PFS)	From first dose of IP to the date of disease progression; up to a later clinical cut-off date of 14 July 2017; for Arms A and B participants were followed for PFS for 31 months and 20 months respectively	Progression-free survival was defined as the time in months from day 1 of treatment to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. RECIST V1.1 criteria includes: - Complete Response (CR) is the disappearance of all target lesions; - Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease (PD); - Progressive Disease is at least a 20% increase in the sum of diameters of target lesions from nadir
Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria	From the first dose of IP to the date of documented first response; up to the data cut-off date of 14 July 2017; maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively.	Overall response rate (ORR) was defined as the percentage of participants who had radiologic CR or PR compared to baseline (radiographic evaluation on the day of or within 28 days prior to randomization) according to RECIST Version 1.1 criteria as determined by the investigator, which was confirmed by repeated radiologic assessment performed no less than 28 days after the criteria for response were first met and occurred between Day 1 of treatment and the start of subsequent anticancer therapy, death or study discontinuation. A complete response and partial response per RECIST V 1.0 criteria was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of diameters of target lesions from baseline.

Trial Locations

Locations (55)

Fox Chase Cancer Center; 🇺🇸 Philadelphia, Pennsylvania, United States

Central Coast Medical Oncology Corporation; 🇺🇸 Santa Maria, California, United States

Northshore University Healthsystem Research Institute; 🇺🇸 Evanston, Illinois, United States

West Jeffersion Medical Center; 🇺🇸 Marrero, Louisiana, United States

Broome Oncology, LLC; 🇺🇸 Johnson City, New York, United States

Somerset Hematology-Oncology Associates; 🇺🇸 Somerville, New Jersey, United States

University of California Los Angeles; 🇺🇸 Santa Monica, California, United States

Reliant Medical Group; 🇺🇸 Worcester, Massachusetts, United States

Cancer Centres of Southwest Okahoma Research; 🇺🇸 Lawton, Oklahoma, United States

St Elizabeth Hospital; 🇺🇸 Youngstown, Ohio, United States

Penn State Milton S Hershey Medical Center; 🇺🇸 Hershey, Pennsylvania, United States

Lynn Cancer Institute; 🇺🇸 Boca Raton, Florida, United States

SUNY Upstate Medical University Medicine Oncology; 🇺🇸 Syracuse, New York, United States

St Mary's Hospital and Regional Medical Center; 🇺🇸 Grand Junction, Colorado, United States

Clinical Research Alliance; 🇺🇸 Lake Success, New York, United States

Brookdale University Hospital and Medical Center; 🇺🇸 Brooklyn, New York, United States

Western Kentucky Hematology and Oncology Group; 🇺🇸 Paducah, Kentucky, United States

Texas Oncology, P.A.-Amarillo; 🇺🇸 Amarillo, Texas, United States

Baptist Cancer Inst; 🇺🇸 Jacksonville, Florida, United States

Ocala Oncology Center; 🇺🇸 Ocala, Florida, United States

Carol G Simon Cancer Center; 🇺🇸 Morristown, New Jersey, United States

Levine Cancer Institute; 🇺🇸 Charlotte, North Carolina, United States

Thomas Jefferson University Medical College; 🇺🇸 Philadelphia, Pennsylvania, United States

Oncology Specialists, S.C.; 🇺🇸 Niles, Illinois, United States

Baylor University Medical Center at Dallas; 🇺🇸 Dallas, Texas, United States

Texas Oncology, PA - Longview; 🇺🇸 Longview, Texas, United States

Perelman Center for Advanced Medicine; 🇺🇸 Philadelphia, Pennsylvania, United States

Allegheny General Hospital; 🇺🇸 Pittsburgh, Pennsylvania, United States

Northwest Cancer Specialists, P.C.; 🇺🇸 Vancouver, Washington, United States

Cancer Center of Kansas; 🇺🇸 Wichita, Kansas, United States

Nebraska Methodist Hospital; 🇺🇸 Omaha, Nebraska, United States

Rocky Mountain Cancer Centers, LLP; 🇺🇸 Denver, Colorado, United States

Franciscan St. Francis Health; 🇺🇸 Indianapolis, Indiana, United States

Henry Ford Health System; 🇺🇸 Detroit, Michigan, United States

Virginia Mason Cancer Center; 🇺🇸 Seattle, Washington, United States

Oregon Health and Science University; 🇺🇸 Portland, Oregon, United States

Ventura County Hematology-Oncology Specialists; 🇺🇸 Oxnard, California, United States

Comprehensive Blood and Cancer Center; 🇺🇸 Bakersfield, California, United States

Genesis Cancer Center; 🇺🇸 Hot Springs, Arkansas, United States

Global Cancer Research Institute (GCRI), Inc.; 🇺🇸 Gilroy, California, United States

Saint Jude Heritage Medical Center; 🇺🇸 Fullerton, California, United States

Saint Barnabas Medical Center; 🇺🇸 Livingston, New Jersey, United States

Good Samaritan Hospital Corvalis; 🇺🇸 Corvallis, Oregon, United States

UTMB Galveston; 🇺🇸 Galveston, Texas, United States

Arizona Clinical Research Center; 🇺🇸 Tucson, Arizona, United States

Dartmouth Hitchcock Medical Center; 🇺🇸 Lebanon, New Hampshire, United States

Florida Hospital Cancer Institute; 🇺🇸 Orlando, Florida, United States

Ochsner Medical Institutions; 🇺🇸 New Orleans, Louisiana, United States

Lineberger Cancer Center; 🇺🇸 Chapel Hill, North Carolina, United States

Forsyth Memorial Hospital, Inc.; 🇺🇸 Winston-Salem, North Carolina, United States

Medstar Health Research Institute; 🇺🇸 Baltimore, Maryland, United States

Center for Cancer and Hematologic Disease; 🇺🇸 Cherry Hill, New Jersey, United States

Regional Cancer Care Associates LLC; 🇺🇸 East Brunswick, New Jersey, United States

Regional Cancer Care Associates LLC- Sparta division; 🇺🇸 Sparta, New Jersey, United States

Montefiore Medical Center; 🇺🇸 Bronx, New York, United States